TrialCompass TCL
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT05010005

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing Ruxolitinib and Duvelisib for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 9 US locations across multiple states.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Ruxolitinib (DRUG): Ruxolitinib 20mg BID | Duvelisib (DRUG): Duvelisib 25mg, 50mg, or 75mg BID

Drugs / treatments
Ruxolitinib, Duvelisib
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

NCT05010005

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing Ruxolitinib and Duvelisib for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 9 US locations across multiple states.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

Ruxolitinib (DRUG): Ruxolitinib 20mg BID | Duvelisib (DRUG): Duvelisib 25mg, 50mg, or 75mg BID

Drugs / treatments: Ruxolitinib, Duvelisib

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 70 patients

Primary endpoint: Assessment for MTD/optimal dose

Ages: 18 Years to —

Start date: 2021-08-12 | Est. completion: 2027-08

Locations

9 US sites · 9 total

Florida, Massachusetts, New Jersey, New York

Contact

Alison Moskowitz, MD | moskowia@mskcc.org | 646-608-3726

Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)

Tags

ENKTL · Maintenance · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05010005

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.